Clincosm LogoSign in Get a demo

Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile

Sponsor
Lille Catholic University (Other)
Overall Status
Completed
CT.gov ID
NCT03025672
Collaborator
(none)
10,445
Enrollment
21.1
Duration (Months)

Study Details

Study Description

Brief Summary

Clostridium difficile is the first cause of nosocomial infectious diarrhea, due to its mode of transmission and its resistance in the environment.

Nosocomiality is defined by the apparition of an infection 48 hours after the patient's hospitalization. Clostridium difficile contamination occurs oro-fecally and is transmitted directly through the hand or from the contaminated environment (during care or not). By implementing prevention and optimal treatment, nosocomial infections are preventable.

A clostridium difficile infection causes an additional cost of patient care for the hospital. This additional cost is principally due to the increase of the length of the stay. It varies according to patient risk factors,and also according to the reason of the hospitalization and can vary from 300 euros (~317$) to more than 25.000 euros (26.460$).

By determining the increase in the length of the stay and the additional cost due to a clostridium difficile infection in the GHICL (Groupement des Hôpitaux de l'Institut Catholique de Lille), prevention will be valued and measures against those infections should be easier to set up.

The main objective of this study is to evaluate the additional cost of an infection by clostridium difficile.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    10445 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Retrospective
    Study Start Date :
    Apr 1, 2015
    Actual Primary Completion Date :
    Jan 1, 2017
    Actual Study Completion Date :
    Jan 1, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    clostridium difficile

    Patients that have been infected by clostridium difficile during their stay in hospital
    no clostridium difficile

    Patients that have not been infected during their stay in hospital.

    Outcome Measures

    Primary Outcome Measures

    1. Difference between patient cost and income for the hospital based on the PMSI rate. [Day 1]

      The difference between the real cost of the patient stay, included the additional costs due to clostridium difficile infection, and the public funding (calculated using the PMSI) for this stay will be computed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients that have stayed in an hospital of the GHICL between January 2013 and September 2015.
    Exclusion Criteria:
    • none

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Lille Catholic University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lille Catholic University
    ClinicalTrials.gov Identifier:
    NCT03025672
    Other Study ID Numbers:
    • OBS-021
    First Posted:
    Jan 19, 2017
    Last Update Posted:
    Jan 19, 2017
    Last Verified:
    Jan 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:
    Infections
    Communicable Diseases
    Clostridium Infections
    Cross Infection

    Study Results

    No Results Posted as of Jan 19, 2017